The goal of this research project is to build upon the Testing and Linkage to Care for Injecting Drug Users (TLC-IDU) parent study and describe post-cure HCV reinfection in a population of people who inject drugs (PWIDs) in Kenya.
In addition to describing reinfection in a substance using cohort, we will identify individual predictors of HCV reinfection in Kenya, as well as identifying individual utilization intervention approaches and dosing that reduce reinfection risk and treatment cite level risk factors (frequency of visits, community vs hospital location etc.). Determining the risk factors specific to reinfection and understanding the impact of concurrent harm reduction interventions will guide service delivery and implementation of HCV elimination strategies in Kenya and throughout the region.
Study Type
OBSERVATIONAL
Enrollment
101
NASCOP
Nairobi, Kenya
HCV Reinfection
The reinfection of patients with hepatitis C after completion of a previous HCV infection treatment.
Time frame: 6-18 months post sustained virologic response (SVR) to HCV treatment.
Evaluate psychoeducational counseling
Brief questionnaire on knowledge, attitude and beliefs of each participant.
Time frame: 6 months
Examine usage of methadone maintenance
Brief questionnaire on services used
Time frame: 12 months
Examine usage of needle exchange programs
Brief questionnaire on services used
Time frame: 12 months
Evaluate psychoeducational counseling
Brief questionnaire on knowledge, attitude and beliefs of each participant.
Time frame: 12 months
HCV reinfection referrals for treatment at Kenyetta National Hospital
Confirmed HCV reinfection cases will receive referrals to Kenyatta National Hospital and Coast General Hospital for treatment and management.
Time frame: 9-16 months post treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.